| pubmed-article:15621781 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15621781 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:15621781 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:15621781 | lifeskim:mentions | umls-concept:C1512162 | lld:lifeskim |
| pubmed-article:15621781 | lifeskim:mentions | umls-concept:C0220615 | lld:lifeskim |
| pubmed-article:15621781 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:15621781 | lifeskim:mentions | umls-concept:C0242602 | lld:lifeskim |
| pubmed-article:15621781 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:15621781 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:15621781 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:15621781 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15621781 | pubmed:dateCreated | 2004-12-28 | lld:pubmed |
| pubmed-article:15621781 | pubmed:abstractText | The feasibility of intensified therapy in adults < 61-years-old with de novo acute myeloid leukemia (AML) was evaluated by adding high-dose cytarabine (HDAC) to conventional induction therapy and in post-remission therapy prior to peripheral blood stem cell transplantation (PBSCT). Patients were treated with conventional induction therapy (daunorubicin days 1-3 and cytarabine days 1-7), followed by HDAC (2 gm/M2) every 12 h ( x 6) on days 8-10. Patients in complete remission (CR) with HLA-matched siblings were assigned to allogeneic PBSCT; the others received two courses of HDAC (3 gm/M2 every 12 h on days 1, 3, and 5) given 1 month apart. Peripheral blood stem cells were then harvested and infused after high-dose chemotherapy. Of 62 eligible, evaluable patients, 47 (76%) achieved CR. The mortality rate was 10% (6 patients); no deaths occurred during the two post-remission courses of HDAC. Fifteen patients were assigned to allogeneic PBSCT and 32 to autologous PBSCT. All surviving patients have been followed for more than 4 years. Including all patients scheduled to receive autoPBSCT in an intent-to-treat analysis, after a median 5-year follow-up the current, non-actuarial, four-year event-free and overall survival was 47% and 47%, respectively. Intensified induction therapy was associated with more toxicity than conventional induction therapy, and the CR rate did not improve. Nevertheless, intensive post-remission therapy was well tolerated, no treatment-related mortality occurred with autologous PBSCT, and disease-free survival and overall survival were lengthy. | lld:pubmed |
| pubmed-article:15621781 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15621781 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15621781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15621781 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15621781 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:15621781 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:Eastern... | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:RoweJacob MJM | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:LitzowMark... | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:DewaldGordon... | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:TallmanMartin... | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:LazarusHillar... | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:StadtmauerEdw... | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:BennettJohn... | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:MillerKenneth... | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:LeeSandra JSJ | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:PaiettaElisab... | lld:pubmed |
| pubmed-article:15621781 | pubmed:author | pubmed-author:CassilethPete... | lld:pubmed |
| pubmed-article:15621781 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15621781 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:15621781 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15621781 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15621781 | pubmed:pagination | 55-61 | lld:pubmed |
| pubmed-article:15621781 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:meshHeading | pubmed-meshheading:15621781... | lld:pubmed |
| pubmed-article:15621781 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15621781 | pubmed:articleTitle | Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). | lld:pubmed |
| pubmed-article:15621781 | pubmed:affiliation | University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA. pcassile@med.miami.edu | lld:pubmed |
| pubmed-article:15621781 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15621781 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15621781 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15621781 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
